311 related articles for article (PubMed ID: 24759263)
1. A preliminary evaluation of efficacy and safety of Wharton's jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus.
Liu X; Zheng P; Wang X; Dai G; Cheng H; Zhang Z; Hua R; Niu X; Shi J; An Y
Stem Cell Res Ther; 2014 Apr; 5(2):57. PubMed ID: 24759263
[TBL] [Abstract][Full Text] [Related]
2. Wharton's jelly mesenchymal stem cells transplantation for critical limb ischemia in patients with type 2 diabetes mellitus: a preliminary report of phase I clinical trial.
Ashoobi MT; Hemmati H; Aghayan HR; Zarei-Behjani Z; Keshavarz S; Babaloo H; Maroufizadeh S; Yousefi S; Farzin M; Vojoudi E
Cell Tissue Res; 2024 Feb; 395(2):211-220. PubMed ID: 38112806
[TBL] [Abstract][Full Text] [Related]
3. Effect and mechanisms of human Wharton's jelly-derived mesenchymal stem cells on type 1 diabetes in NOD model.
Hu J; Wang Y; Wang F; Wang L; Yu X; Sun R; Wang Z; Wang L; Gao H; Fu Z; Zhao W; Yan S
Endocrine; 2015 Feb; 48(1):124-34. PubMed ID: 24590294
[TBL] [Abstract][Full Text] [Related]
4. Undifferentiated Wharton's Jelly Mesenchymal Stem Cell Transplantation Induces Insulin-Producing Cell Differentiation and Suppression of T-Cell-Mediated Autoimmunity in Nonobese Diabetic Mice.
Tsai PJ; Wang HS; Lin GJ; Chou SC; Chu TH; Chuan WT; Lu YJ; Weng ZC; Su CH; Hsieh PS; Sytwu HK; Lin CH; Chen TH; Shyu JF
Cell Transplant; 2015; 24(8):1555-70. PubMed ID: 25198179
[TBL] [Abstract][Full Text] [Related]
5. Single high-dose intravenous injection of Wharton's jelly-derived mesenchymal stem cell exerts protective effects in a rat model of metabolic syndrome.
Chan AML; Ng AMH; Yunus MHM; Idrus RH; Law JX; Yazid MD; Chin KY; Yusof MRM; Ng SN; Koh B; Lokanathan Y
Stem Cell Res Ther; 2024 Jun; 15(1):160. PubMed ID: 38835014
[TBL] [Abstract][Full Text] [Related]
6. Intravenous vs intraperitoneal transplantation of umbilical cord mesenchymal stem cells from Wharton's jelly in the treatment of streptozotocin-induced diabetic rats.
El-Hossary N; Hassanein H; El-Ghareeb AW; Issa H
Diabetes Res Clin Pract; 2016 Nov; 121():102-111. PubMed ID: 27693839
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of 2 Intracavernous Injections of Allogeneic Wharton's Jelly-Derived Mesenchymal Stem Cells in Diabetic Patients with Erectile Dysfunction: Phase 1/2 Clinical Trial.
Al Demour S; Adwan S; Jafar H; Rahmeh R; Alhawari H; Awidi A
Urol Int; 2021; 105(11-12):935-943. PubMed ID: 34384079
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of apelin in Wharton' jelly mesenchymal stem cell reverses insulin resistance and promotes pancreatic β cell proliferation in type 2 diabetic rats.
Gao LR; Zhang NK; Zhang Y; Chen Y; Wang L; Zhu Y; Tang HH
Stem Cell Res Ther; 2018 Dec; 9(1):339. PubMed ID: 30526660
[TBL] [Abstract][Full Text] [Related]
9. Wharton's jelly-derived mesenchymal stem cells attenuate sepsis-induced organ injury partially via cholinergic anti-inflammatory pathway activation.
Capcha JMC; Rodrigues CE; Moreira RS; Silveira MD; Dourado P; Dos Santos F; Irigoyen MC; Jensen L; Garnica MR; Noronha IL; Andrade L; Gomes SA
Am J Physiol Regul Integr Comp Physiol; 2020 Jan; 318(1):R135-R147. PubMed ID: 31596111
[TBL] [Abstract][Full Text] [Related]
10. Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus.
Hu J; Yu X; Wang Z; Wang F; Wang L; Gao H; Chen Y; Zhao W; Jia Z; Yan S; Wang Y
Endocr J; 2013; 60(3):347-57. PubMed ID: 23154532
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of cell cycle and WNT pathway-related genes accounts for differences in the growth and differentiation potential of Wharton's jelly and bone marrow-derived mesenchymal stem cells.
Batsali AK; Pontikoglou C; Koutroulakis D; Pavlaki KI; Damianaki A; Mavroudi I; Alpantaki K; Kouvidi E; Kontakis G; Papadaki HA
Stem Cell Res Ther; 2017 Apr; 8(1):102. PubMed ID: 28446235
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and clinical applications of Wharton's jelly-derived mesenchymal stromal cells.
Liau LL; Ruszymah BHI; Ng MH; Law JX
Curr Res Transl Med; 2020 Jan; 68(1):5-16. PubMed ID: 31543433
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Wharton Jelly-Derived Mesenchymal Stromal Cells and Their Conditioned Media in the Treatment of a Rat Spinal Cord Injury.
Chudickova M; Vackova I; Machova Urdzikova L; Jancova P; Kekulova K; Rehorova M; Turnovcova K; Jendelova P; Kubinova S
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31547264
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of umbilical cord-derived stem cells for diabetes mellitus: a meta-analysis study.
Kassem DH; Kamal MM
Stem Cell Res Ther; 2020 Nov; 11(1):484. PubMed ID: 33198815
[TBL] [Abstract][Full Text] [Related]
15. Comparison between the effect of human Wharton's jelly-derived mesenchymal stem cells and levetiracetam on brain infarcts in rats.
Abd El Motteleb DM; Hussein S; Hasan MM; Mosaad H
J Cell Biochem; 2018 Dec; 119(12):9790-9800. PubMed ID: 30171723
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Fe
Li X; Wei Z; Wu L; Lv H; Zhang Y; Li J; Yao H; Zhang H; Yang B; Xu X; Jiang J
Biomater Sci; 2020 Oct; 8(19):5362-5375. PubMed ID: 32869785
[TBL] [Abstract][Full Text] [Related]
17. Differentiation of human mesenchymal stem cells (MSC) to dopaminergic neurons: A comparison between Wharton's Jelly and olfactory mucosa as sources of MSCs.
Alizadeh R; Bagher Z; Kamrava SK; Falah M; Ghasemi Hamidabadi H; Eskandarian Boroujeni M; Mohammadi F; Khodaverdi S; Zare-Sadeghi A; Olya A; Komeili A
J Chem Neuroanat; 2019 Mar; 96():126-133. PubMed ID: 30639339
[TBL] [Abstract][Full Text] [Related]
18. Wharton's Jelly-Derived Mesenchymal Stem Cell Transplantation in a Patient with Hypoxic-Ischemic Encephalopathy: A Pilot Study.
Kabataş S; Civelek E; İnci Ç; Yalçınkaya EY; Günel G; Kır G; Albayrak E; Öztürk E; Adaş G; Karaöz E
Cell Transplant; 2018 Oct; 27(10):1425-1433. PubMed ID: 30203688
[TBL] [Abstract][Full Text] [Related]
19. Chondrogenic induction of mesenchymal stromal/stem cells from Wharton's jelly embedded in alginate hydrogel and without added growth factor: an alternative stem cell source for cartilage tissue engineering.
Reppel L; Schiavi J; Charif N; Leger L; Yu H; Pinzano A; Henrionnet C; Stoltz JF; Bensoussan D; Huselstein C
Stem Cell Res Ther; 2015 Dec; 6():260. PubMed ID: 26718750
[TBL] [Abstract][Full Text] [Related]
20. Obestatin can potentially differentiate Wharton's jelly mesenchymal stem cells into insulin-producing cells.
El-Asfar RK; Kamal MM; Abd El-Razek RS; El-Demerdash E; El-Mesallamy HO
Cell Tissue Res; 2018 Apr; 372(1):91-98. PubMed ID: 29159483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
